Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03549559 · ClinicalTrials.gov registry record · NA
Imaging Histone Deacetylase in the Heart
A NA study of Diabetes and Aortic Valve Stenosis, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 96
- Enrollment target
- 1
- Study location
NCT03549559: Recruiting NA study of Diabetes and Aortic Valve Stenosis, sponsored by Massachusetts General Hospital.
NCT03549559 is a NA study of Diabetes and Aortic Valve Stenosis that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 96 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03549559, a NA study of Diabetes and Aortic Valve Stenosis, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 96 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall goal of this PET-MR imaging trial is to evaluate 11C-Martinostat, a histone deacetylase targeted radioligand, in patients with aortic stenosis, individuals with diabetes, and healthy volunteers.
Primary Outcome
Comparison of regional HDAC activity as measured by standard uptake value ratio (SUVR) of 11C-Martinostat between patient subjects with aortic stenosis or diabetes and healthy volunteers
Conditions Studied
Interventions
- DRUG 11C-Martinostat
- DEVICE PET-MRI
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2018-09-07 |
| Est. Completion | 2026-09-01 |
| Phase | NA |
What NCT03549559 shows while recruiting
NCT03549559 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (97% lower).
The record links to 4 conditions, with Diabetes appearing as the primary indexed condition, and to 2 interventions - of which 11C-Martinostat is the first listed.
NCT03549559 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03549559 about?
NCT03549559 is a clinical study titled "Imaging Histone Deacetylase in the Heart". The overall goal of this PET-MR imaging trial is to evaluate 11C-Martinostat, a histone deacetylase targeted radioligand, in patients with aortic stenosis, individuals with diabetes, and healthy volunteers.
What is the current status of trial NCT03549559?
This trial is currently recruiting. It is a NA study. The enrollment target is 96 participants. The study started on 2018-09-07. Estimated completion is 2026-09-01.
What conditions does trial NCT03549559 study?
This clinical trial studies the following conditions: Diabetes, Aortic Valve Stenosis, Heart Failure With Normal Ejection Fraction, Left Ventricular Hypertrophy.
What interventions are being tested in trial NCT03549559?
The interventions under investigation include: 11C-Martinostat (DRUG), PET-MRI (DEVICE).
Who is sponsoring clinical trial NCT03549559?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03549559 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03549559's enrollment target sits among peer trials
96 198th of 338 higher than 141 of 338 other Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of 2-Week Continuous Glucose Monitoring on Glycemic Management in Patients New-to-Insulin on Hospital Discharge
RECRUITING · NA
-
Effects of Whole vs. Nonfat Milk Consumption on Body Composition in Children
RECRUITING · NA
-
Efficacy of Viome's Precision Nutrition Program Towards Reducing HbA1c
RECRUITING · NA
-
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
RECRUITING · NA
-
Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
RECRUITING · NA
-
Bringing Advocacy Via Digital Guide to the Emergency Department (Project BADGE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
- NCT04056013 · 96 participants · NA
Vicryl Rapide Versus Nonabsorbable Suture
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI